1 drug(s) with this reaction
1,041 total reports
Acute Lymphocytic Leukaemia Recurrent has been reported as an adverse reaction across 1 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 1,041 adverse event reports mention acute lymphocytic leukaemia recurrent in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with acute lymphocytic leukaemia recurrent, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have acute lymphocytic leukaemia recurrent listed in their FDA adverse event reports, sorted by report count:
In addition to acute lymphocytic leukaemia recurrent, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
1 drug(s) manufactured by Amgen Inc have acute lymphocytic leukaemia recurrent listed in their FDA adverse event reports: BLINATUMOMAB.
There are a combined 1,041 reports of acute lymphocytic leukaemia recurrent across 1 Amgen Inc drug(s) in the FDA adverse event database.